
Search
Selected Filters
Filter Results
Displaying 11–20 of 357 news results
-
May 15, 2025
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Despite missing the primary endpoint, the treatment improved vision for some patients.
-
May 13, 2025
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
May 12, 2025
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
May 9, 2025
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Apr 7, 2025
Atsena Receives $150 Million in New Financing to Advance XLRS and Preclinical Gene Therapy Programs
The company has reported encouraging results from its LCA1 and XLRS gene therapy clinical trials.
-
Mar 11, 2025
Luxa Reports Vision Improvements in Clinical Trial of its RPE Stem Cell Therapy for Dry AMD
Patients with worse vision at trial enrollment had greatest vision improvements.
-
Mar 7, 2025
Neurotech’s Encapsulated Cell Technology Receives FDA Approval for Treatment of MacTel
The technology was previously funded by the Foundation for the treatment of retinitis pigmentosa and dry age-related macular degeneration.
-
Feb 28, 2025
Adverum Advancing Wet AMD Gene Therapy into Phase 3 Clinical Trials
In earlier clinical trials, the emerging gene therapy greatly reduced the treatment burden associated with injections of approved anti-VEGF therapies.
-
Feb 24, 2025
LCA4 Gene Therapy Restores Meaningful Vision for Blind Children
MeiraGTx hopes to apply for marketing approval in the UK for the gene therapy.
-
Feb 19, 2025
RD Fund Invests in Perceive Pharma for Development of Neuroprotective Therapies
Perceive Pharma is a spin out of Perceive Biotherapeutics.